Use of complement monoclonal antibody eculizumab in Shiga toxin producing Escherichia coli associated hemolytic uremic syndrome: A review of current evidence-Reference-Cited by-同舟云学术

Use of complement monoclonal antibody eculizumab in Shiga toxin producing Escherichia coli associated hemolytic uremic syndrome: A review of current evidence

Published:2019-07-09 Issue:11 Volume:66 Page:
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Mahat Upendra¹^ORCID,Matar Raed Bou²,Rotz Seth J.¹^ORCID

Affiliation:

1. Department of Pediatric Hematology Oncology and BMTCleveland Clinic Children's Cleveland Ohio

2. Center for Pediatric NephrologyCleveland Clinic Children's Cleveland Ohio

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pbc.27913

Reference25 articles.

1. Eculizumab in the treatment of Shiga toxin haemolytic uraemic syndrome

2. The complement system in hemolytic‐uremic syndrome in childhood;Monnens L;Clin Nephrol,1980

3. Activation of the alternative pathway of complement during the acute phase of typical haemolytic uraemic syndrome

4. Shiga Toxin–Induced Complement-Mediated Hemolysis and Release of Complement-Coated Red Blood Cell–Derived Microvesicles in Hemolytic Uremic Syndrome

5. Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli–induced hemolytic uremic syndrome

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Microorganisms responsible for neonatal diarrhea;Remington and Klein's Infectious Diseases of the Fetus and Newborn Infant;2025

2. Successful application of eculizumab in typical haemolytic uraemic syndrome;BMJ Case Reports;2024-08

3. Treating myasthenia gravis beyond the eye clinic;Eye;2024-05-24

4. HUS and TTP: traversing the disease and the age spectrum;Seminars in Nephrology;2023-11

5. Complement inhibitors in pediatric kidney diseases: new therapeutic opportunities;Pediatric Nephrology;2023-09-21